Metastatic HER2+ Cancer | Norton Healthcare

Indication: Metastatic HER2+ Cancer

A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)

Sub-indication: Breast Cancer

Study Type: Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Seagen Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.